Enclomiphene — Dosing, Cycles, Half-Life & Side Effects
Enclomiphene is a selective estrogen receptor modulator (SERM) with a half-life of ~10 hours (Wiehle et al. 2014, Fertility and Sterility, doi: 10.1016/j.fertnstert.2014.05.017). Trans-isomer of clomiphene — pure SERM antagonist without zuclomiphene accumulation. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.
Quick Facts
| Class | SERMs |
|---|---|
| Half-life | ~10 hours (Wiehle et al. 2014, Fertility and Sterility, doi: 10.1016/j.fertnstert.2014.05.017) |
| Elimination half-life (free hormone) | ~10-10.5 hours (pure trans-isomer; lacks the slow-clearing zuclomiphene enantiomer present in racemic clomiphene) |
| Detection window | 14 days |
| Hepatotoxicity | Low |
| Suppression | 0/10 |
| Administration | oral |
| US regulatory status | compounded |
Typical Dosing Ranges
Common dose range: 12.5-25mg/day (Wiehle 2014 phase 2 RCT, N=124 secondary hypogonadal men). Source: compounded only in the US — verify the compounding pharmacy and dose accuracy before use.
Cycle length: 4-6 weeks
Time to steady state: ~2 days
Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.
Stacking Considerations
- Incompatible combinations per internal rule set: Clomiphene (Clomid), Tamoxifen (Nolvadex).
PCT Requirements
- Depot clearance estimate: ~2 days post-last-dose before SERM start (5 × apparent depot half-life of 10h).
- Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
- Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.
Side Effect Profile
- NOT FDA-approved (received Complete Response Letter in 2015 as 'Androxal'; only available compounded in the US)
- Compounded supply means inconsistent dose accuracy and identity verification across pharmacies
- Expensive vs racemic clomiphene
- Less long-term safety data than racemic clomiphene
Known Interactions
No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.
Related compounds
Monitoring (Bloodwork & Vitals)
- Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
- Lipid panel (total cholesterol, HDL, LDL, triglycerides)
- CBC (hemoglobin, hematocrit — watch for erythrocytosis)
- Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
- Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)
Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.
Frequently Asked Questions
What is the half-life of Enclomiphene?
Enclomiphene has a half-life of approximately ~10 hours (Wiehle et al. 2014, Fertility and Sterility, doi: 10.1016/j.fertnstert.2014.05.017). Clearance estimate: 10h × 5 = 50h = 2.1 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.
What is the typical dose range for Enclomiphene?
Commonly reported ranges for Enclomiphene: 12.5-25mg/day (Wiehle 2014 phase 2 RCT, N=124 secondary hypogonadal men). Source: compounded only in the US — verify the compounding pharmacy and dose accuracy before use.. Cycle length: 4-6 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.
Does Enclomiphene suppress natural testosterone?
Enclomiphene causes minimal suppression of the HPTA axis (score 0/10). PCT may still be advisable depending on stack and duration.
Is Enclomiphene liver toxic?
Hepatotoxicity rating: Low. Non-17αα compound — liver stress is lower but still warrants periodic monitoring during a cycle.
What is Enclomiphene typically used for?
Enclomiphene is commonly used for: PCT — single-SERM monotherapy preferred over racemic clomiphene when available and supply is trusted, Secondary hypogonadism (off-label per Wiehle 2014 RCT), All experience levels. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.
Citations
- Wiehle R et al.. 2014. J Mens Health — Elimination half-life approximately 10-10.5 hours
- Wiehle R et al.. 2013. BJU Int — Phase II: 6.25, 12.5, and 25mg doses all increased testosterone into normal range within 2 weeks; 25mg showed maximal effect
- Wiehle R et al.. 2014. Fertil Steril — Enclomiphene stimulates testosterone while preventing oligospermia
- Handelsman DJ / Shankara-Narayana N et al.. 2022. Eur J Endocrinol — HPTA recovery median 52 weeks post-AAS; informs enclomiphene PCT duration rationale; enclomiphene as single-SERM alternative to racemic clomiphene (no zuclomiphene accumulation)
- Wiehle 2014 + Endocrine Society. 2018. J Clin Endocrinol Metab — Enclomiphene short-course PCT — minimal CV impact; no VTE signal in Wiehle 2014 RCT
- de Oliveira Vilar Neto JF et al.. 2021. Andrologia — Systematic review: only 4/38 known-outcome AAS-induced hypogonadism cases fully recovered; informs enclomiphene monotherapy PCT selection — observational data, NOT a dual-SERM recommendation (PROJECT.md constraint)
- Repros Therapeutics / FDA. 2015. FDA Complete Response Letter — Repros Therapeutics filed enclomiphene citrate as 'Androxal' for FDA approval (secondary hypogonadism indication). FDA issued a Complete Response Letter in 2015 declining approval and requesting additional studies; Repros did not pursue further. Enclomiphene is therefore NOT FDA-approved in the US and is available only via compounding pharmacies. Compounded supply has variable dose accuracy and identity verification — recommend buying only from 503A/503B pharmacies with documented USP-grade APIs and recent third-party assays. regulatoryStatus: 'compounded'.
- Wiehle R et al. Enclomiphene citrate dose ranging in secondary hypogonadal men. BJU Int. 2013
- FDA Complete Response Letter (Repros Therapeutics 'Androxal' NDA 2015) — basis for regulatoryStatus 'compounded'.
Disclaimer
StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Enclomiphene. Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.